Article Details
Retrieved on: 2022-08-18 05:58:40
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Zynteglo is cleared for transfusion-dependent beta thalassemia, but will come at a cost of $2.8 million per patient. Published Aug.
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here